Literature DB >> 25125483

Iatrogenic parkinsonism: the role of flunarizine and cinnarizine.

Rita Miguel1, Ana Sofia Aleixo Correia2, Paulo Bugalho2.   

Abstract

We performed a clinical report based, descriptive and retrospective study, aimed at comparing Flunarizine/Cinnarizine-induced parkinsonism (FCIP) patients and Parkinson's disease (PD) patients. The FCIP group (n = 30) presented a lower frequency of rigidity and unilateral tremor than the PD group (n = 70). All FCIP patients improved, 13 after dopaminergic treatment. FCIP patients who improved spontaneously presented lower frequency of rigidity, compared with the other FCIP subgroup and PD group. FCIP patients who did not improve spontaneously showed a clinical pattern similar to PD patients.

Entities:  

Keywords:  Calcium channel blockers; Parkinson's disease; cinnarizine; drug-induced parkinsonism; flunarizine; nigrostriatal pathway

Mesh:

Substances:

Year:  2014        PMID: 25125483     DOI: 10.3233/JPD-140414

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  4 in total

1.  Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study.

Authors:  Hsiu-Li Lin; Hsiu-Chen Lin; Yuan-Fu Tseng; Shih-Chang Chen; Chien-Yeh Hsu
Journal:  Eur J Clin Pharmacol       Date:  2016-12-16       Impact factor: 2.953

2.  Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype.

Authors:  Renato P Munhoz; Delcio Bertucci Filho; Hélio A G Teive
Journal:  Neurol Sci       Date:  2016-11-16       Impact factor: 3.307

3.  Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine.

Authors:  Kai-Ming Jhang; Jing-Yang Huang; Oswald Ndi Nfor; Yu-Chun Tung; Wen-Yuan Ku; Chun-Te Lee; Yung-Po Liaw
Journal:  Eur J Clin Pharmacol       Date:  2017-04-06       Impact factor: 2.953

4.  Flunarizine related movement disorders: a nationwide population-based study.

Authors:  Kai-Ming Jhang; Jing-Yang Huang; Oswald Ndi Nfor; Yu-Chun Tung; Wen-Yuan Ku; Cheng-Feng Jan; Yung-Po Liaw
Journal:  Sci Rep       Date:  2019-02-08       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.